A patient described rapid improvement in her frown lines in an Instagram promotion for Jeuveau. FDA acknowledged that her account might accurately reflect her experience. It still found the advertisement misleading.
The agency’s September 28 untitled letter to Evolus separates two questions that an authentic testimonial can blur: what happened to this patient, and what the advertisement tells other patients to expect.
A truthful personal account does not establish the broader treatment claim conveyed by the advertisement around it.
The Advertisement Brought Different Measures Together
FDA contrasted the principal Day 30 efficacy endpoint, requiring at least a two-point improvement assessed by both patient and investigator, with an exploratory Day 2 endpoint using a one-point change measured by a single rater rather than the composite. It identified statistical limitations in the exploratory analysis, including the absence of a multiplicity adjustment and of a pre-specified alpha.
The concern was not simply that the advertisement mentioned an early result. It was that the presentation conflated different measures of improvement and overstated the demonstrated speed and magnitude of benefit.
Improvement is not a single, interchangeable outcome. A small early change and a larger later change answer different questions. Presenting them together can invite the audience to read the strength of the later result into the timing of the earlier one.
That is why reviewing the accuracy of each number is only part of reviewing an advertisement. The relationship the presentation creates between the numbers matters too.
An Individual Result Does Not Establish an Expected Result
FDA said the testimonial did not adequately support the suggestion that all patients would experience a similar response. The disclaimer “Individual results may vary” did not cure the impression.
The letter does not establish that this patient was an outlier. That label would go beyond the record. The problem is the inference from one person’s account to a broader promise.
Selecting a successful patient can demonstrate that the person reports a favorable experience. It cannot, by itself, establish how often the result occurs, how much improvement other patients should expect, or how confidently the effect can be attributed to treatment.
Those questions require evidence appropriate to the claim. Verifying that the patient is real and that the quotation is accurate does not answer them.
The Principle Predates Instagram
This is a recent application of established advertising principles. In its 2009 announcement of revised Endorsement Guides, the Federal Trade Commission explained that advertisements conveying an atypical consumer experience as typical must clearly disclose generally expected results. The same revision removed the earlier safe harbor that had allowed a disclaimer such as “results not typical” to serve instead.
The FTC’s current guidance on endorsements likewise explains that advertisers need support for the results conveyed by testimonials. These materials describe the broader advertising principle. FDA’s prescription-drug requirements govern the Jeuveau letter.
An advertiser cannot obtain through a patient’s voice an evidentiary shortcut unavailable for its own product claims.
That does not make patient stories inappropriate. They can communicate experiences that matter to patients. The review must address both the story’s authenticity and the claim created by its selection, editing, captions, and placement alongside study results.
